TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster Outlook
Source: SeekingAlpha
2026-04-18 22:32:28 ET
Overview
My last look at TG Therapeutics stock ( TGTX ) was in January. I upgraded from Hold to Strong Buy . TGTX has risen 17% versus S&P 500 ( SPY ) gains of 2.7%....
Read the full article on Seeking Alpha
For further details see:
TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster Outlook
TG Therapeutics Inc.
NASDAQ: TGTX
TGTX Trading
2.13% G/L:
$41.39 Last:
1,092,407 Volume:
$40.58 Open:
TGTX Latest News
June 03, 2026 07:30:00 am
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
June 02, 2026 07:30:00 am
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
June 01, 2026 07:30:00 am
TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
May 28, 2026 07:30:00 am
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
TGTX Stock Data
$4,661,971,279
141,867,445
0.11%
146
N/A
Biotechnology & Life Sciences
Healthcare
US
Morrisville
